IBDEI01V ; ; 06-AUG-2013
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;AUG 06, 2013
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,2026,1,8,0)
 ;;=8^Acquired Hemophilia
 ;;^UTILITY(U,$J,358.3,2026,2)
 ;;=^340502
 ;;^UTILITY(U,$J,358.3,2027,0)
 ;;=286.53^^23^166^6
 ;;^UTILITY(U,$J,358.3,2027,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2027,1,1,0)
 ;;=1^286.53
 ;;^UTILITY(U,$J,358.3,2027,1,8,0)
 ;;=8^Antiphospholipid w/ Hemor d/o
 ;;^UTILITY(U,$J,358.3,2027,2)
 ;;=^340503
 ;;^UTILITY(U,$J,358.3,2028,0)
 ;;=286.59^^23^166^17
 ;;^UTILITY(U,$J,358.3,2028,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2028,1,1,0)
 ;;=1^286.59
 ;;^UTILITY(U,$J,358.3,2028,1,8,0)
 ;;=8^Oth Hemor d/o d/t Anticoagulant
 ;;^UTILITY(U,$J,358.3,2028,2)
 ;;=^340504
 ;;^UTILITY(U,$J,358.3,2029,0)
 ;;=286.6^^23^166^13
 ;;^UTILITY(U,$J,358.3,2029,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2029,1,1,0)
 ;;=1^286.6
 ;;^UTILITY(U,$J,358.3,2029,1,8,0)
 ;;=8^Defibrination Syndrome
 ;;^UTILITY(U,$J,358.3,2029,2)
 ;;=^35673
 ;;^UTILITY(U,$J,358.3,2030,0)
 ;;=286.7^^23^166^1
 ;;^UTILITY(U,$J,358.3,2030,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2030,1,1,0)
 ;;=1^286.7
 ;;^UTILITY(U,$J,358.3,2030,1,8,0)
 ;;=8^Acquired Coagulation Factor Def
 ;;^UTILITY(U,$J,358.3,2030,2)
 ;;=^2235
 ;;^UTILITY(U,$J,358.3,2031,0)
 ;;=286.9^^23^166^12
 ;;^UTILITY(U,$J,358.3,2031,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2031,1,1,0)
 ;;=1^286.9
 ;;^UTILITY(U,$J,358.3,2031,1,8,0)
 ;;=8^Defective Coagulation,Unspec
 ;;^UTILITY(U,$J,358.3,2031,2)
 ;;=^87267
 ;;^UTILITY(U,$J,358.3,2032,0)
 ;;=287.0^^23^166^4
 ;;^UTILITY(U,$J,358.3,2032,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2032,1,1,0)
 ;;=1^287.0
 ;;^UTILITY(U,$J,358.3,2032,1,8,0)
 ;;=8^Allergic Purpura
 ;;^UTILITY(U,$J,358.3,2032,2)
 ;;=^101365
 ;;^UTILITY(U,$J,358.3,2033,0)
 ;;=287.1^^23^166^24
 ;;^UTILITY(U,$J,358.3,2033,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2033,1,1,0)
 ;;=1^287.1
 ;;^UTILITY(U,$J,358.3,2033,1,8,0)
 ;;=8^Qualitative Platelet Defects
 ;;^UTILITY(U,$J,358.3,2033,2)
 ;;=^101922
 ;;^UTILITY(U,$J,358.3,2034,0)
 ;;=287.2^^23^166^18
 ;;^UTILITY(U,$J,358.3,2034,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2034,1,1,0)
 ;;=1^287.2
 ;;^UTILITY(U,$J,358.3,2034,1,8,0)
 ;;=8^Oth Nonthrombocytopenic Purpuras
 ;;^UTILITY(U,$J,358.3,2034,2)
 ;;=^87741
 ;;^UTILITY(U,$J,358.3,2035,0)
 ;;=287.31^^23^166^15
 ;;^UTILITY(U,$J,358.3,2035,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2035,1,1,0)
 ;;=1^287.31
 ;;^UTILITY(U,$J,358.3,2035,1,8,0)
 ;;=8^Immune Thrombocytopenic Purpura
 ;;^UTILITY(U,$J,358.3,2035,2)
 ;;=^332746
 ;;^UTILITY(U,$J,358.3,2036,0)
 ;;=287.32^^23^166^14
 ;;^UTILITY(U,$J,358.3,2036,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2036,1,1,0)
 ;;=1^287.32
 ;;^UTILITY(U,$J,358.3,2036,1,8,0)
 ;;=8^Evan's Syndrome
 ;;^UTILITY(U,$J,358.3,2036,2)
 ;;=^332747
 ;;^UTILITY(U,$J,358.3,2037,0)
 ;;=287.41^^23^166^21
 ;;^UTILITY(U,$J,358.3,2037,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2037,1,1,0)
 ;;=1^287.41
 ;;^UTILITY(U,$J,358.3,2037,1,8,0)
 ;;=8^Posttransfusion Purpura
 ;;^UTILITY(U,$J,358.3,2037,2)
 ;;=^339609
 ;;^UTILITY(U,$J,358.3,2038,0)
 ;;=287.49^^23^166^19
 ;;^UTILITY(U,$J,358.3,2038,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2038,1,1,0)
 ;;=1^287.49
 ;;^UTILITY(U,$J,358.3,2038,1,8,0)
 ;;=8^Oth Secondary Thrombocytopenia
 ;;^UTILITY(U,$J,358.3,2038,2)
 ;;=^339610
 ;;^UTILITY(U,$J,358.3,2039,0)
 ;;=287.8^^23^166^20
 ;;^UTILITY(U,$J,358.3,2039,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2039,1,1,0)
 ;;=1^287.8
 ;;^UTILITY(U,$J,358.3,2039,1,8,0)
 ;;=8^Oth Spec Hemorrhagic Conditions
 ;;^UTILITY(U,$J,358.3,2039,2)
 ;;=^88074
 ;;^UTILITY(U,$J,358.3,2040,0)
 ;;=287.9^^23^166^29
 ;;^UTILITY(U,$J,358.3,2040,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2040,1,1,0)
 ;;=1^287.9
 ;;^UTILITY(U,$J,358.3,2040,1,8,0)
 ;;=8^Unspec Hemorrhagic Conditions
 ;;^UTILITY(U,$J,358.3,2040,2)
 ;;=^123920
 ;;^UTILITY(U,$J,358.3,2041,0)
 ;;=205.00^^23^167^32
 ;;^UTILITY(U,$J,358.3,2041,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2041,1,1,0)
 ;;=1^205.00
 ;;^UTILITY(U,$J,358.3,2041,1,8,0)
 ;;=8^Myeloid Leukemia w/o Remission
 ;;^UTILITY(U,$J,358.3,2041,2)
 ;;=^267531
 ;;^UTILITY(U,$J,358.3,2042,0)
 ;;=205.01^^23^167^31
 ;;^UTILITY(U,$J,358.3,2042,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2042,1,1,0)
 ;;=1^205.01
 ;;^UTILITY(U,$J,358.3,2042,1,8,0)
 ;;=8^Myeloid Leukemia in Remission
 ;;^UTILITY(U,$J,358.3,2042,2)
 ;;=^267532
 ;;^UTILITY(U,$J,358.3,2043,0)
 ;;=205.10^^23^167^18
 ;;^UTILITY(U,$J,358.3,2043,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2043,1,1,0)
 ;;=1^205.10
 ;;^UTILITY(U,$J,358.3,2043,1,8,0)
 ;;=8^Chr Myeloid Leukemia w/o Remission
 ;;^UTILITY(U,$J,358.3,2043,2)
 ;;=^267533
 ;;^UTILITY(U,$J,358.3,2044,0)
 ;;=205.11^^23^167^17
 ;;^UTILITY(U,$J,358.3,2044,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2044,1,1,0)
 ;;=1^205.11
 ;;^UTILITY(U,$J,358.3,2044,1,8,0)
 ;;=8^Chr Myeloid Leukemia in Remission
 ;;^UTILITY(U,$J,358.3,2044,2)
 ;;=^267534
 ;;^UTILITY(U,$J,358.3,2045,0)
 ;;=289.0^^23^167^50
 ;;^UTILITY(U,$J,358.3,2045,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2045,1,1,0)
 ;;=1^289.0
 ;;^UTILITY(U,$J,358.3,2045,1,8,0)
 ;;=8^Secondary Polycythemia
 ;;^UTILITY(U,$J,358.3,2045,2)
 ;;=^186856
 ;;^UTILITY(U,$J,358.3,2046,0)
 ;;=238.4^^23^167^48
 ;;^UTILITY(U,$J,358.3,2046,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2046,1,1,0)
 ;;=1^238.4
 ;;^UTILITY(U,$J,358.3,2046,1,8,0)
 ;;=8^Polycythemia Rubra Vera
 ;;^UTILITY(U,$J,358.3,2046,2)
 ;;=^96105
 ;;^UTILITY(U,$J,358.3,2047,0)
 ;;=288.9^^23^167^67
 ;;^UTILITY(U,$J,358.3,2047,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2047,1,1,0)
 ;;=1^288.9
 ;;^UTILITY(U,$J,358.3,2047,1,8,0)
 ;;=8^Unspecified Dis Of W B C
 ;;^UTILITY(U,$J,358.3,2047,2)
 ;;=^267993
 ;;^UTILITY(U,$J,358.3,2048,0)
 ;;=289.81^^23^167^49
 ;;^UTILITY(U,$J,358.3,2048,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2048,1,1,0)
 ;;=1^289.81
 ;;^UTILITY(U,$J,358.3,2048,1,8,0)
 ;;=8^Primary Hypercoagulable State
 ;;^UTILITY(U,$J,358.3,2048,2)
 ;;=^329886
 ;;^UTILITY(U,$J,358.3,2049,0)
 ;;=238.75^^23^167^29
 ;;^UTILITY(U,$J,358.3,2049,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2049,1,1,0)
 ;;=1^238.75
 ;;^UTILITY(U,$J,358.3,2049,1,8,0)
 ;;=8^Myelodysplastic Syndrome
 ;;^UTILITY(U,$J,358.3,2049,2)
 ;;=^334031
 ;;^UTILITY(U,$J,358.3,2050,0)
 ;;=289.9^^23^167^66
 ;;^UTILITY(U,$J,358.3,2050,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2050,1,1,0)
 ;;=1^289.9
 ;;^UTILITY(U,$J,358.3,2050,1,8,0)
 ;;=8^Unspecified Blood Disease
 ;;^UTILITY(U,$J,358.3,2050,2)
 ;;=^55344
 ;;^UTILITY(U,$J,358.3,2051,0)
 ;;=205.02^^23^167^30
 ;;^UTILITY(U,$J,358.3,2051,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2051,1,1,0)
 ;;=1^205.02
 ;;^UTILITY(U,$J,358.3,2051,1,8,0)
 ;;=8^Myeloid Leukemia in Relapse
 ;;^UTILITY(U,$J,358.3,2051,2)
 ;;=^336470
 ;;^UTILITY(U,$J,358.3,2052,0)
 ;;=205.12^^23^167^16
 ;;^UTILITY(U,$J,358.3,2052,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2052,1,1,0)
 ;;=1^205.12
 ;;^UTILITY(U,$J,358.3,2052,1,8,0)
 ;;=8^Chr Myeloid Leukemia in Relapse
 ;;^UTILITY(U,$J,358.3,2052,2)
 ;;=^336471
 ;;^UTILITY(U,$J,358.3,2053,0)
 ;;=205.20^^23^167^59
 ;;^UTILITY(U,$J,358.3,2053,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2053,1,1,0)
 ;;=1^205.20
 ;;^UTILITY(U,$J,358.3,2053,1,8,0)
 ;;=8^Subacute Myeloid Leuk w/o Remiss
 ;;^UTILITY(U,$J,358.3,2053,2)
 ;;=^336857
 ;;^UTILITY(U,$J,358.3,2054,0)
 ;;=205.21^^23^167^58
 ;;^UTILITY(U,$J,358.3,2054,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2054,1,1,0)
 ;;=1^205.21
 ;;^UTILITY(U,$J,358.3,2054,1,8,0)
 ;;=8^Subacute Myeloid Leuk in Remiss
 ;;^UTILITY(U,$J,358.3,2054,2)
 ;;=^267536
 ;;^UTILITY(U,$J,358.3,2055,0)
 ;;=205.22^^23^167^57
 ;;^UTILITY(U,$J,358.3,2055,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2055,1,1,0)
 ;;=1^205.22
 ;;^UTILITY(U,$J,358.3,2055,1,8,0)
 ;;=8^Subacute Myeloid Leuk in Relapse
 ;;^UTILITY(U,$J,358.3,2055,2)
 ;;=^336472
 ;;^UTILITY(U,$J,358.3,2056,0)
 ;;=205.30^^23^167^35
 ;;^UTILITY(U,$J,358.3,2056,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2056,1,1,0)
 ;;=1^205.30
 ;;^UTILITY(U,$J,358.3,2056,1,8,0)
 ;;=8^Myeloid Sarcoma w/o Remission
 ;;^UTILITY(U,$J,358.3,2056,2)
 ;;=^336858
 ;;^UTILITY(U,$J,358.3,2057,0)
 ;;=205.31^^23^167^34
 ;;^UTILITY(U,$J,358.3,2057,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2057,1,1,0)
 ;;=1^205.31
 ;;^UTILITY(U,$J,358.3,2057,1,8,0)
 ;;=8^Myeloid Sarcoma in Remission
 ;;^UTILITY(U,$J,358.3,2057,2)
 ;;=^267538
 ;;^UTILITY(U,$J,358.3,2058,0)
 ;;=205.32^^23^167^33
 ;;^UTILITY(U,$J,358.3,2058,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2058,1,1,0)
 ;;=1^205.32
 ;;^UTILITY(U,$J,358.3,2058,1,8,0)
 ;;=8^Myeloid Sarcoma in Relapse
 ;;^UTILITY(U,$J,358.3,2058,2)
 ;;=^336473
 ;;^UTILITY(U,$J,358.3,2059,0)
 ;;=205.80^^23^167^44
 ;;^UTILITY(U,$J,358.3,2059,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2059,1,1,0)
 ;;=1^205.80
 ;;^UTILITY(U,$J,358.3,2059,1,8,0)
 ;;=8^Oth Myeloid Leukemia w/o Remission
 ;;^UTILITY(U,$J,358.3,2059,2)
 ;;=^336859
 ;;^UTILITY(U,$J,358.3,2060,0)
 ;;=205.81^^23^167^43
 ;;^UTILITY(U,$J,358.3,2060,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2060,1,1,0)
 ;;=1^205.81
 ;;^UTILITY(U,$J,358.3,2060,1,8,0)
 ;;=8^Oth Myeloid Leukemia in Remission
 ;;^UTILITY(U,$J,358.3,2060,2)
 ;;=^267540
 ;;^UTILITY(U,$J,358.3,2061,0)
 ;;=205.82^^23^167^42
 ;;^UTILITY(U,$J,358.3,2061,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2061,1,1,0)
 ;;=1^205.82
 ;;^UTILITY(U,$J,358.3,2061,1,8,0)
 ;;=8^Oth Myeloid Leukemia in Relapse
 ;;^UTILITY(U,$J,358.3,2061,2)
 ;;=^336474
 ;;^UTILITY(U,$J,358.3,2062,0)
 ;;=205.90^^23^167^65
 ;;^UTILITY(U,$J,358.3,2062,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2062,1,1,0)
 ;;=1^205.90
 ;;^UTILITY(U,$J,358.3,2062,1,8,0)
 ;;=8^Unspec Myeloid Leuk w/o Remission
 ;;^UTILITY(U,$J,358.3,2062,2)
 ;;=^336860
 ;;^UTILITY(U,$J,358.3,2063,0)
 ;;=205.91^^23^167^64
 ;;^UTILITY(U,$J,358.3,2063,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2063,1,1,0)
 ;;=1^205.91
 ;;^UTILITY(U,$J,358.3,2063,1,8,0)
 ;;=8^Unspec Myeloid Leuk in Remission
